Imaxio’s IMX313 pro-immunogenic technology used in tuberculosis vaccine human clinical trial
Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis More...